VivoSeq
Oncology

Small Cell Carcinoma

20

Pipeline Programs↗

4

Active Trials↗

12

Companies Involved↗

Small Cell Carcinoma is an emerging landscape with 20 programs across 12 companies. The most active players are Teva, Avyxa, Roche.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

67/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

1 program

Phase 1A

Avyxa

2 programs

Phase 2Roche logo

Roche

2 programs

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2AstraZeneca logo

AstraZeneca

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

65%

Small molecule

13 of 20 classified programs — the dominant modality here.

35%ALL OTHERSMonoclonal antibody630%Antibody–drug conjugate15%

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

11

clinical trials

Unknown status4 · 36%
Recruiting3 · 27%
Completed2 · 18%
Not yet recruiting1 · 9%
Terminated1 · 9%

Clinical Trials

Trial Activity

11 trials

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
Recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT06464068·66 enrolled
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06228066·45 enrolled
A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06161532·60 enrolled
A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma
Not yet recruiting·—·Phase 2·NCT06478264·40 enrolled
Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma
Completed·NNational University Hospital, Singapore·Phase 2·NCT00212043·74 enrolled
Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma
Completed·UUniversity of Washington·Phase 1·NCT02881125·2 enrolled
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Terminated·NNew Mexico Cancer Research Alliance·Phase 2·NCT00391586·45 enrolled
Study of Developing an Optimal Gemcitabine Based Regimen to Treat Elderly Patients With Advanced Non-Small Cell Carcinoma
Unknown status·UUlsan University Hospital·Phase 2·NCT00625352·48 enrolled
Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma
Unknown status·SSun Yat-sen University·Phase 2·NCT05760053·33 enrolled
Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy
Unknown status·SSun Yat-sen University·Phase 2·NCT03811379·43 enrolled
Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)
Unknown status·National Cancer Center, Korea·Phase 1/2·NCT01027676·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)